SELLAS Life Sciences Group, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
SELLAS Life Sciences Group, Inc. (SLS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2017-11-09
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.87.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2014-03-31 was $1.30.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2016 was $31.44, a 3879.75% increase from fiscal 2015.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2015 was $0.79.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2013 was $1.21, a 42.35% increase from fiscal 2012.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2012 was $0.85.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $31.44 10-K · filed 2017-03-15 | |||
| 2016-09-30 | $1.57 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $1.57 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $0.87 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $0.79 10-K/A · filed 2016-04-15 | |||
| 2015-09-30 | $0.79 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $0.85 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $1.31 8-K · filed 2015-12-04 | |||
| 2014-09-30 | $1.31 10-Q · filed 2014-11-05 | |||
| 2014-06-30 | $1.30 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $1.30 10-Q · filed 2014-05-06 | |||
| 2013-12-31 | $1.21 10-K · filed 2014-03-17 | |||
| 2013-09-30 | $0.88 10-Q/A · filed 2013-11-07 | |||
| 2013-06-30 | $0.85 10-Q · filed 2013-08-09 | |||
| 2012-12-31 | $0.85 10-K · filed 2013-03-12 | |||
| 2012-09-30 | $0.76 10-Q · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |